Lantheus (NASDAQ:LNTH) Posts Earnings Results, Beats Expectations By $0.08 EPS

Lantheus (NASDAQ:LNTH) announced its quarterly earnings results on Thursday. The medical equipment provider reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.08, Briefing.com reports. Lantheus had a return on equity of 20.57% and a net margin of 3.51%. The company had revenue of $66.01 million during the quarter, compared to analyst estimates of $55.77 million. During the same quarter last year, the firm posted $0.27 earnings per share. The firm’s revenue was down 23.0% on a year-over-year basis.

Shares of NASDAQ:LNTH opened at $13.48 on Friday. Lantheus has a 1-year low of $8.67 and a 1-year high of $27.12. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.37 and a quick ratio of 2.41. The business has a fifty day moving average price of $14.59 and a 200-day moving average price of $14.48. The company has a market capitalization of $582.43 million, a PE ratio of 44.93 and a beta of 1.26.

A number of brokerages recently commented on LNTH. BidaskClub raised Lantheus from a “sell” rating to a “hold” rating in a research note on Tuesday, June 23rd. Zacks Investment Research raised Lantheus from a “sell” rating to a “hold” rating in a research note on Friday, July 10th. CJS Securities raised Lantheus from a “market perform” rating to an “outperform” rating in a research report on Tuesday, June 16th. Finally, Jefferies Financial Group began coverage on Lantheus in a research report on Monday, June 29th. They set a “buy” rating and a $29.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $29.00.

In other news, insider John J. Bolla sold 2,422 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $14.29, for a total transaction of $34,610.38. Following the completion of the transaction, the insider now directly owns 60,419 shares in the company, valued at $863,387.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mary Anne Heino sold 3,000 shares of the firm’s stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $16.02, for a total value of $48,060.00. Following the transaction, the chief executive officer now owns 604,793 shares of the company’s stock, valued at $9,688,783.86. The disclosure for this sale can be found here. Insiders have sold 27,547 shares of company stock valued at $436,892 over the last 90 days. Corporate insiders own 2.08% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

See Also: What are municipal bonds?

Earnings History for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.